
Keywords: Mild; Moderate; Asthma; Lebrikizumab; AE; adverse event; AQLQ(S); Standardised Asthma Quality of Life Questionnaire; ATA; anti-therapeutic antibodies; FeNO; fractional exhaled nitric oxide; FEV1; forced expiratory volume in 1â¯s; HLGT; high level group t